Learn how a blood test is being used to detect the Alzheimer’s disease biomarker, phosphorylated tau, in research and clinical diagnosis
In deciphering the pathophysiology of neurological disorders such as Alzheimer’s disease or dementia, early-stage biomarkers are often present at very low levels. Most conventional immunoassays used to detect these biomarkers tend to have colorimetric outputs that lack the sensitivity or the dynamic range required to detect and reliably measure low-abundance analytes.
Traditional ELISA assays or colorimetric multiplexed assays often require sample dilution to accommodate higher loading volumes. This further dilutes the biomarker concentration, making it either undetectable or placing it below the lowest detectable limit of the assay, thereby rendering the quantitative output unreliable. To add to this challenge, one of the biggest bottlenecks when dealing with rare or valuable samples obtained from patients is its limited volume, which means repeat testing may not be feasible.
In these circumstances, translational and clinical researchers alike benefit from an immunoassay that reliably detects and quantifies low-level analytes, provides an unambiguous digital readout, and requires no sample dilution. In this SelectScience® article, we speak with Dr. David Wilson, VP of Clinical Strategy at Quanterix, about using sensitive assays to detect trace concentrations of biomarkers in early disease stages. Read the full article here.
Related Posts
Spatial Analysis
Snapshots of Health Innovation From the Edison Awards
Building the Tools Parkinson’s Disease Research Needs
A Q&A with Kishore Malyavantham, PhD, VP of R&D at Quanterix and Co-Investigator, PD-BUILD Quanterix has been named a Co-Investigator institution in PD-BUILD (Biomarker Utilization, Innovation, and Laboratory-to-Deployment), a new project…
Quanterix Named to ASAP CRN 2026 PD-BUILD Program with MJFF Support
Part of a global effort to advance Parkinson’s disease biomarkers through standardized, scalable assay development Quanterix has been selected as a Co-Investigator institution in the PD-BUILD program, part of the…
Neurology
Why biomarkers are no longer supplemental
Quanterix makes the case with ctDNA in oncology, p-tau217 in Alzheimer’s and a lab model built for longitudinal, regulatory-grade data. Biomarkers have moved from “nice-to-have” to the backbone of drug…
Neurology
Preparing The Market for Blood-Based Biomarkers
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, outlined strategies for integrating blood-based biomarkers into routine clinical care pathways, ensuring minimal disruption for patients and clinicians. Watch the full…
Neurology
Challenges of Positioning an Ultra-Sensitive Platform
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed challenges in positioning Simoa in the precision health market, stressing its accuracy and reliability in diverse populations. Watch the full…
Neurology
Translating Complex Scientific Findings into Actionable Insights
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed translating complex scientific findings into actionable insights for healthcare providers and stakeholders, emphasizing the importance of early disease detection. Watch…
Neurology
AI and the rise of blood-based biomarkers heralds new era for neurological diagnostics
Advances in blood-based biomarkers are transforming early and accurate Alzheimer’s disease detection, offering less invasive, cost-effective alternatives to traditional diagnostic methods. Quanterix, a company working at the very frontiers of…